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Objectives: Decreased susceptibility to ﬂuoroquinolones has become a major problem for the successful
therapy of human infections caused by Salmonella enterica, especially the life-threatening typhoid and para-
typhoid fevers.
Methods: By using Luminex xTAG beads, we developed a rapid, reliable and cost-effective multiplexed genotyp-
ing assay for simultaneously detecting 11 mutations in gyrA, gyrB and parE of S. enterica serovars Typhi and
Paratyphi A that result in nalidixic acid resistance (Nal
R) and/or decreased susceptibility to ﬂuoroquinolones.
Results: This assay yielded unambiguous single nucleotide polymorphism calls on extracted DNA from 292 iso-
lates of Salmonella Typhi (Nal
R¼223 and Nal
S¼69) and 106 isolates of Salmonella Paratyphi A (Nal
R¼24 and
Nal
S¼82). All of the 247 Nal
R Salmonella Typhi and Salmonella Paratyphi A isolates were found to harbour at
least one of the target mutations, with GyrA Phe-83 as the most common one (143/223 for Salmonella Typhi
and 18/24 for Salmonella Paratyphi A). We also identiﬁed three GyrB mutations in eight Nal
S Salmonella Typhi
isolates (six for GyrB Phe-464, one for GyrB Leu-465 and one for GyrB Asp-466), and mutations GyrB Phe-464
and GyrB Asp-466 seem to be related to the decreased ciproﬂoxacin susceptibility phenotype in Salmonella
Typhi. This assay can also be used directly on boiled single colonies.
Conclusions: The assay presented here would be useful for clinical and reference laboratories to rapidly screen
quinolone-resistant isolates of Salmonella Typhi and Salmonella Paratyphi A, and decipher the underlying
genetic changes for epidemiological purposes.
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Introduction
Salmonella enterica serovars Typhi and Paratyphi A are invasive,
life-threatening human pathogens, causing the systemic dis-
eases typhoid and paratyphoid fever, respectively, which still
pose signiﬁcant threats to public health in many developing
countries. In 2000, a population-based study estimated
that the global disease burdens associated with typhoid and
paratyphoid fever were 21.6 million cases (with 216000
deaths) and 5.4 million cases, respectively.
1 Resistance and
decreased susceptibility to ﬂuoroquinolones in Salmonella,
often accompanied by resistance to nalidixic acid (Nal
R), will
# The Author 2010. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.
org/licenses/by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original
work is properly cited.
J Antimicrob Chemother 2010; 65: 1631–1641
doi:10.1093/jac/dkq175 Advance Access publication 28 May 2010
1631lead to treatment failures for typhoid and paratyphoid fever.
2,3
The most common cause of resistance to nalidixic acid and
decreased susceptibility to ﬂuoroquinolones in serovar Typhi is
amino acid substitutions in the quinolone resistance-determining
region (QRDR) of the DNA gyrase subunit GyrA.
4,5 Mutations in
the QRDR of the other subunit of DNA gyrase (GyrB) and both
subunits of DNA topoisomerases IV (ParC and ParE) will also
result in increased resistance to quinolones.
6,7
The rapid detection of Nal
R Salmonella Typhi and Salmonella
Paratyphi A is vital in clinical practice to guide antibiotic
therapy, and the traditional disc-diffusion protocol is still the
most commonly used method for identifying resistant isolates.
Microbiologists have attempted to develop molecular assays
for rapidly screening Nal
R isolates and for determining underlying
genetic changes in resistant isolates as well. These assays
include denaturing HPLC (dHPLC),
8 real-time PCR,
9,10 restriction
fragment length polymorphism,
11 pyrosequencing,
12 high-
resolution melting curve assay
13 and mismatch ampliﬁcation
mutation assay.
14 However, none of these assays is capable of
detecting multiple single nucleotide polymorphisms (SNPs) in
different genes simultaneously with medium to high throughput.
We have previously described six different mutations in the
QRDR of GyrA within Salmonella Typhi,
5 and have also identiﬁed
additional mutations in GyrB and ParE in unpublished work,
some of which are associated with decreased susceptibility to
ﬂuoroquinolones without concomitant resistance to nalidixic
acid (P. Roumagnac and M. Achtman). In order to efﬁciently
test for the presence of these mutations individually and in com-
bination, we designed a rapid and cost-effective multiplex geno-
typing assay based on Luminex xTAG beads, which can
simultaneously screen for 11 mutations in gyrA, gyrB and parE
of Salmonella Typhi and Salmonella Paratyphi A.
Materials and methods
Bacterial isolates
Four sets of isolates including a total of 292 Salmonella Typhi and 106
Salmonella Paratyphi A were tested in this study. Strains of Salmonella
Typhi had been isolated between 1991 and 2006 in Asia, Europe and
Africa, while Salmonella Paratyphi A strains were isolated between
1917 and 2006 across Asia, Europe, Africa and America. Twelve
Salmonella Typhi isolates with known mutations in gyrA, gyrB and parE
were used to develop the assay. These mutations are based on
genomic sequences for four isolates [CT18, 150(98)S, E02-2759 and
AG3]
15,16 and on mutations discovered by dHPLC plus sequencing in
eight others.
5 The assay was validated with a second group of 193
Salmonella Typhi isolates, for which the corresponding regions in gyrA,
gyrB and parE had been tested previously by dHPLC (unpublished for
gyrB and parE, P. Roumagnac and M. Achtman).
5 A third group of 87
isolates of Salmonella Typhi that had not been previously tested was
also subjected to the Luminex assay, including 80 Nal
R and 7 Nal
S
isolates. Lastly, 106 isolates of Salmonella Paratyphi A (24 Nal
R and 82
Nal
S) were also included in this study. The MICs for isolates of nalidixic
acid (resistant breakpoint 32 mg/L) and ciproﬂoxacin (resistant break-
point 4 mg/L) were determined according to the guidelines of the
CLSI,
17 and genomic DNAs were extracted using standard protocols.
Mutations and oligonucleotides
We tested 11 mutations in nine polymorphic sites, including two biallelic
polymorphisms (Bips) in gyrA (gyrA247 and gyrA260), three Bips in gyrB
(gyrB1391, gyrB1394 and gyrB1398) and two Bips in parE (parE1246 and
parE1258), as well as two triallelic polymorphisms (Trips) in gyrA
(gyrA248 and gyrA259) (Figure 1).
5 Primers were designed with PrimerPlex
V1.0 (PREMIER Biosoft International, USA) and are shown in Table 1,
including 6 primers for amplifying the three gene fragments in one
multiplex PCR and 20 allele-speciﬁc primer extension (ASPE) primers
for detecting all 11 mutations. The 20 ASPE primers target each of
the wild-type and mutant alleles by allele-speciﬁc nucleotides at the
3′ end, and contain unique TAGs (speciﬁc 24-mer oligonucleotide
s e q u e n c e sa s‘ t a g s ’f o rd i f f e r e n tA S P Ep r i m e r s )a tt h e5 ′ end that are
reverse complements to the anti-TAGs on xTAG beads (Luminex Corp.,
USA). They also contain degenerate nucleotides at internal positions,
which will ensure primer extension despite known polymorphisms
neighbouring the target SNPs in all isolates from Salmonella Typhi as
well as Salmonella Paratyphi A. All oligonucleotides were synthesized
by Invitrogen Corp.
Multiplex PCR
The overall scheme of the assay is shown in Figure 2. The following
steps were carried out in 96-well microplates. Each 10 mL multiplex PCR
consisted of 5 mLo f2 × Multiplex PCR Master Mix (Qiagen, Germany),
1 mL of a mixture of 0.5 mM PCR primers for amplifying gyrA, gyrB
and parE, and 4 mL of template DNA (5 ng/mL). One well per microplate
contained 4 mL of distilled water (dH2O) instead of template DNA and
served as a blank control. PCR cycling was performed in a four-block
DNA Engine Tetrad 2 Thermocycler (Bio-Rad Inc., USA), with an initial
denaturation at 958C for 10 min, followed by 30 cycles at 948C for 30 s,
588C for 30 s and 728C for 30 s, and a ﬁnal extension step at 728C for
3 min.
Exo-SAP treatment
To remove the unincorporated PCR primers and dNTPs, 1 mL of Exo-SAP
containing 5 U of exonuclease I (Exo) and 0.5 U of shrimp alkaline phos-
phatase (SAP) (USB Corp., Germany) was added to each multiplex PCR
product and mixed. The mixture was then incubated at 378C for
30 min, followed by 10 min at 808C to inactivate the enzymes.
Multiplex ASPE
The ASPE used here follows the protocol recommended by Luminex
(http://www.luminexcorp.com/support/protocols/xtag_protocols.html).
Brieﬂy, each 10 mL multiplex ASPE mixture reaction contained 5 mLo f
Exo-SAP-treated multiplex PCR product, 0.3 U of Tsp DNA polymerase
(Invitrogen), 25 nM ASPE primer mixture for all 11 SNPs (Table 1), 5 mM
dATP/dTTP/dGTP and biotin-dCTP (Invitrogen), 20 mM Tris-HCl (pH 8.4),
50 mM KCl and 1.25 mM MgCl2. Thermocycling was performed at 958C
for 5 min, followed by 25 cycles of 948C for 30 s, 558C for 30 s and
728C for 1 min, and a ﬁnal extension at 728C for 3 min.
Hybridization
A mixture of 20 distinct Luminex xTAG beads (shown in the last column of
Table 1) containing 250 beads/mL for each bead type was prepared in 2×
Tm hybridization buffer (0.4 M NaCl/0.2 M Tris/0.16% Triton X-100, pH
8.0). Then, 2 mL of the bead mixture was added per well containing
10 mL of ASPE products, followed by 23 mLo f2 × Tm hybridization
buffer and 15 mLo fd H 2O for a total volume of 50 mL. A bead control con-
sisted of 2 mL of bead mixture, 23 mLo f2 × Tm hybridization buffer and
25 mLo fd H 2O. The hybridization mixture was then incubated at 958C
for 1 min and 378C for 30 min.
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The hybridization mixture was centrifuged at 3220 g for 3 min and the
supernatant was discarded. The xTAG bead pellets were then washed
twice by adding 75 mLo f1 × Tm hybridization buffer (0.2 M NaCl/0.1 M
Tris/0.08% Triton X-100, pH 8.0), centrifuged at 3220 g for 3 min and
the supernatant discarded. Then, 75 mLo f1 × Tm hybridization buffer
containing 2 mg/L streptavidin-R-phycoerythrin (Invitrogen, USA) was
added to each well and the mixture was incubated at 378C for 15 min.
For detection, 50 mL of the ﬁnal solution was injected into a Luminex
200 station (Luminex Corp., USA), at a sample plate temperature of
378C. Fluorescence signals were measured for 100 beads for each of
the 20 types of beads.
SNP calling
The Luminex station provides median ﬂuorescence intensity (MFI) values
for 100 beads of each bead type for all tested samples. The MFI values for
samples were corrected by subtracting the values of the bead control,
and the blank control was used to ensure that contamination and unspe-
ciﬁc signals were not introduced during the multiplex PCR and ASPE
process. SNPs were called with the software MasterPlex (MiraiBio, USA)
only when the background-corrected MFI was .300 and the ratio of
MFIcalled allele/(MFIwild allele+MFImutant allele) was .0.9. For the two Trips
in gyrA (Figure 1 and Table 2), the denominator consisted of the MFI
for the wild-type plus both of the mutant alleles.
Reproducibility
DNA from isolate CT18 was used to evaluate the reproducibility of the
assay in ﬁve independent repeats, following the steps described above.
Direct detection from bacterial colonies
Twelve random isolates of Salmonella Paratyphi A (4 Nal
S and 8 Nal
R)
were streaked to single colonies on trypticase soy agar plates. For each
isolate, a single colony was resuspended in 100 mLo fH 2O and incubated
at 958C for 15 min in order to kill the bacteria and release genomic DNA.
After centrifugation, the supernatants were transferred to new tubes and
used as templates for multiplex PCR.
Results
Development of the Luminex xTAG assay
The Luminex xTAG genotyping assay consists of four steps
(Figure 2), as follows.
(i) A multiplex PCR to amplify three gene fragments of gyrA,
gyrB and parE containing 11 target SNPs (Table 1), after which
unincorporated dNTPs and PCR primers are removed by
Exo-SAP treatment.
gyrA (+) Salmonella Typhi  
GAT T AGTGTATGACACC
GAT T
GAT T AGTGTAT
GAT T AGTGTAT
GAT T
AGTGTAT GACACC
GAT T AGTGTATG
82 86 85 84 83 88 87
GAT TCCGCAGTGTATGACACC
Ser Asp
(a)
ATGCT
462 466 465 464 463 467 (b)
ATGCTTTCCTCCCAGGA AGTG
ATG CTTTCC T
Glu Gln Ser
461
TTCCTTGTGGA A GGGGA TTCG
416 420 419 418 417 421 (c)
Asp Leu
415
TTCCTTGTGGA A GGGGA TTCG
T TCCTTGTGGAAGGG
T TC TGGAAGGGGATTCG
GAT C C
T AGTGTATGACACC
A
CCGC
CCGC
CCGC
CGC
CCGC
CGC
CGCAGTGTATGACACC
A AC AC C
T AC AC C
G CACC
C TCCTCT CAGGAAGTG
T CCAGGAAGTG
ATGCTTTCCT CCC T GGA AGTG
ATGCTTTCCTCCCAGGAC GTG
T TTG
A ATTCG
gyrA (+) Salmonella Paratyphi A 
gyrA259 _T (Tyr-87) 
gyrA259 _A (Asn-87)
gyrA248 _A (Tyr-83) 
gyrA247 _C (Pro-83)
gyrA248 _T (Phe-83)
gyrA260 _G (Gly-87)
gyrB (+) Salmonella Typhi
gyrB (+) Salmonella Paratyphi A 
gyrB1398 _C (Asp-466)
gyrB1391 _T (Phe-464) 
gyrB1394 _T (Leu-465) 
parE (+) Salmonella Typhi 
parE (+) Salmonella Paratyphi A
parE1246 _T (Phe-416)
parE1258 _A (Asn-420) 
Figure 1. Multiple alignments of partial gyrA, gyrB and parE fragments in Salmonella Typhi and Salmonella Paratyphi A. Wild-type alleles for each gene
are indicated by a plus symbol (+). The mutations tested in this paper are shown in black squares and the wild-type amino acid is indicated on top of
the alignments for codons containing target mutations. The amino acids for mutations are shown in brackets after the allele names. (a) Alignment of
gyrA showing polymorphisms in codons 83 and 87, of which two are triallelic polymorphisms (Trips). (b) Alignment of gyrB with three mutations. Two
silent mutations in Salmonella Paratyphi A are shown in grey squares. (c) Alignment of parE with two mutations.
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JAC(ii) A multiplex primer extension step using 20 ASPE primers,
during which biotin-dCTP is incorporated if there is a perfect
match at the 3′ end. This step includes oligonucleotide primers
speciﬁc for each of the wild-type and mutated alleles at each
of the Bips and Trips (Figure 1), and which contain allele-speciﬁc
unique TAG sequences. Tsp polymerase is so speciﬁc that only
one of the alternative primers is extended for each nucleotide
position and the other primers for that position serve as internal
controls.
(iii) The ASPE products are hybridized to a mixture of 20 types
of Luminex xTAG beads, each containing one anti-TAG sequence
that is complementary to one of the TAG sequences appended to
an ASPE primer. After washing the beads, the ﬂuorescent dye
streptavidin-R-phycoerythrin is added to bind to biotin-dCTP in
the ASPE products.
(iv) The ASPE products/xTAG beads/streptavidin-R-
phycoerythrin complex is quantiﬁed with a Luminex station,
which calculates the MFI for 100 beads of each type. The
entire procedure was conducted in two 96-well plates per test,
with one plate for step (i) and the second one for the other
three steps.
MFI values were corrected by subtracting the bead control
and arbitrarily set to 0.5 if this correction resulted in negative
values. Examples of such corrected data for the 12 reference
isolates used to develop this assay are shown in Table 2. SNPs
were called when corrected MFI was .300 and the ratio of
MFIcalled allele/(MFIwild allele+MFImutant allele)w a s.0.9. These
calls agreed completely with prior assignments based on
dHPLC and sequencing.
5 In Table 2, the MFI values of called
alleles ranged from .1000 to 5961. In contrast, the MFI of
uncalled alleles ranged from 0.5 to 31.5, only slightly greater
than the values for the H2O control (12.0–29.0). These results
demonstrate that the Luminex assay provides a tool to unam-
biguously call all the targeted SNPs.
Reproducibility of the assay was tested by ﬁve independent
trials with isolate CT18 (Figure 3). CT18 is wild-type for all the
nine polymorphic positions in gyrA, gyrB and parE. MFI values
for mutant alleles were almost negligible whereas corrected
MFI values for wild-type alleles were strong. Positive MFI results
showed considerable variation between individual tests, possibly
reﬂecting variability between different runs in PCR and ASPE efﬁ-
ciencies. However, the ratios of MFIcalled allele/(MFIwild allele+
MFImutant allele) were very uniform, with an average ratio of
called MFI of .0.99 and a coefﬁcient of variation of ,0.5%.
The MFI of called alleles was always .50 times higher than
that of the uncalled ones. The use of MFI ratios instead of net
Table 1. Detailed information on mutations in gyrA, gyrB and parE, and oligonucleotides used in this study
Gene PCR primer pairs Amplicon ASPE primer sequence
a Target allele
b Amino acid xTAG beads
c
gyrA GCCCTTCAATGCTGATGTCTTC 805 bp CAATAAACTATACTTCTTCACTAAATGGTGTCATACACTGCGDA gyrA247_T(+) GyrA Ser-83 13
TCTCCTCTGTGTCGCCTCTG ATACTTCATTCATTCATCAATTCAATGGTGTCATACACTGCGDG gyrA247_C GyrA Pro-83 15
CAATTCATTTACCAATTTACCAATGATGGTGTCATACACTGCGG gyrA248_C(+) GyrA Ser-83 7
TAATCTTCTATATCAACATCTTACGATGGTGTCATACACTGCGA gyrA248_T GyrA Phe-83 9
TACAAATCATCAATCACTTTAATCGATGGTGTCATACACTGCGT gyrA248_A GyrA Tyr-83 11
TACACTTTATCAAATCTTACAATCGCCATACGAACGATGGTGYC gyrA259_G(+) GyrA Asp-87 3
TACATTACCAATAATCTTCAAATCGCCATACGAACGATGGTGYT gyrA259_A GyrA Asn-87 4
CAATTCAAATCACAATAATCAATCGCCATACGAACGATGGTGYA gyrA259_T GyrA Tyr-87 5
CTTTAATCTCAATCAATACAAATCCGCCATACGAACGATGGTGT gyrA260_A(+) GyrA Asp-87 1
CTTTATCAATACATACTACAATCACGCCATACGAACGATGGTGC gyrA260_G GyrA Gly-87 2
gyrB ACTGGCGGATTGTCAGGAAC 640 bp AATCCTTTCTTTAATCTCAAATCAGCTTCGACAAGATGCTTTCCTC gyrB1391_C(+) GyrB Ser-464 21
ATCGGCTTCGGTCAGAGTTG CTTTAATCTACACTTTCTAACAATGCTTCGACAAGATGCTTTCCTT gyrB1391_T GyrB Phe-464 81
TCAATTACCTTTTCAATACAATACCGACAAGATGCTTTCCTYYCA gyrB1394_A(+) GyrB Gln-465 24
CTTTTCAATTACTTCAAATCTTCACGACAAGATGCTTTCCTYYCT gyrB1394_T GyrB Leu-465 25
TTACTCAAAATCTACACTTTTTCAAAGATGCTTTCCTYYCWGGAA gyrB1398_A(+) GyrB Glu-466 26
CTTTTCAAATCAATACTCAACTTTAAGATGCTTTCCTYYCWGGAC gyrB1398_C GyrB Asp-466 27
parE ATACGGTATAGCGGCGGTAG 493 bp TCAATCAATTACTTACTCAAATACGCCGAATCCCCTTCCACAAG parE1246_C(+) ParE Leu-416 19
CGGAACAACTGGCAGAGATG CTATCTATCTAACTATCTATATCAGCCGAATCCCCTTCCACAAA parE1246_T ParE Phe-416 78
AATCAATCTTCATTCAAATCATCAGGAACCGCCTGCCGAATC parE1258_G(+) ParE Asp-420 16
CTTTAATCCTTTATCACTTTATCAGGAACCGCCTGCCGAATT parE1258_A ParE Asn-420 17
aThe italic nucleotides for each ASPE primer are the TAG sequences provided by Luminex. The nucleotides in bold are degenerate sites (D, A or G or T; Y,
C or T; and W, A or T).
bAlleles detected by individual ASPE primers. The subscript numbers indicate the nucleotide positions in gyrA, gyrB and parE, followed by nucleotides at
these positions. ‘(+)’ indicates wild-type alleles. Because the primer design was carried out on the CT18 genome and the reading frame of gyrA is on
the minus strand of the genome, nucleotides in gyrA alleles are complementary to the 3′-end nucleotides in corresponding ASPE primers. In total, 11
mutations at nine polymorphic sites are shown, including two triallelic polymorphisms (Trips) in gyrA (gyrA248 and gyrA259), two biallelic polymorph-
isms (Bips) in gyrA, three Bips in gyrB and two Bips in parE.
cDifferent xTAG beads used to call the alleles in the Luminex assay. The numbers are indexed to the coupled anti-TAG, which are reverse complimen-
tary to the italic TAG sequences appended to the ASPE primers.
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yields unambiguous SNP calling results.
The assays just described were performed with puriﬁed DNA
as template. We also tested whether boiled single colonies
from agar plates could be used as a template with eight Nal
R
and four Nal
S isolates of Salmonella Paratyphi A. The results
were congruent with results obtained with puriﬁed DNA from
these isolates, namely all four Nal
S isolates contained only wild-
type alleles, seven Nal
R isolates were called as GyrA Phe-83 and
one Nal
R isolate was called as GyrA Tyr-83. This result indicates
that this assay could be used by clinical microbiologists immedi-
ately after cultivation of Salmonella isolates. Starting with tem-
plate DNA, testing 188 samples, two H2O controls and two
bead controls in two 96-well microplates took a total of  7h
(Figure 2), with hands-on time of ,1 h. Hence, the assay can
be completed within 1 working day, producing 2068 datapoints
(188 samples×11 SNPs).
Validation with a larger panel of isolates
A panel of 205 isolates of Salmonella Typhi (including the 12 iso-
lates used to develop the assay) was tested to validate the
Luminex assay. The mutation proﬁles for gyrA, gyrB and parE of
these isolates had previously been determined, either by whole
genome sequencing or dHPLC (Table 3).
5,15,16
The results with the 62 Nal
S isolates were fully consistent with
previous dHPLC data: 54 were wild-type for all the targeted SNPs;
six contained GyrB Phe-464; one was GyrB Leu-465; and one was
GyrB Asp-466. All of the 143 Nal
R isolates harboured at least one
of the target mutations. The mutation proﬁles of these isolates
were: GyrA Phe-83 (77 isolates); GyrA Tyr-83 (18 isolates); GyrA
Pro-83 (1 isolate); GyrA Asn-87 (4 isolates); GyrA Tyr-87
(1 isolate); GyrA Gly-87 (10 isolates); GyrA Phe-83+ParE
Asn-420 (31 isolates); and GyrA Phe-83+ParE Phe-416 (1
isolate). These results were only 88.8% (127/143) concordant
with the prior dHPLC results, because 11 isolates were GyrA
T
A
A G
B
dCTP
B
dCTP
B
SA
PE
B
SA
PE
G
SA
PE
SA
PE
A
B B
G
Multiplex PCR
1.5 h
Exo-SAP 
Multiplex ASPE
2.0 h
Hybridization with beads
Washing
Incubation with phycoerythrin
1.5 h
Luminex readout
2 h
A
T
A
G
B
dCTP
SA
PE
Genomic DNA
Multiplex PCR primers
Multiplex ASPE primers
with TAG
Multiplex Luminex xTAG beads
with anti-TAG
Biotin-dCTP
Streptavidin-R-phycoerythrin
High MFI signal
Allele ‘A’ called
Background MFI signal
Allele ‘G’ not called
Figure 2. Overview of the Luminex xTAG assay developed in this paper. More details of all steps can be found in the Materials and methods section.
The estimated time for each step is shown on the left, based on testing two 96-well plates of samples. Only one fragment with one biallelic
polymorphism site (Bip) is shown for illustrative purposes.
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JACPhe-83 according to dHPLC whereas they were GyrA Phe-83+
ParE Asn-420 based on the Luminex assay, and ﬁve isolates
were GyrA Tyr-83 in dHPLC and GyrA Phe-83 in the Luminex
assay. The 16 discrepancies were resolved by direct sequencing
using the primers listed in Table 1. The direct sequencing
results conﬁrmed the Luminex SNP calls for all 16 isolates,
showing that the Luminex assay made the correct calls, includ-
ing multiple SNPs, for all Salmonella Typhi isolates (both Nal
S
and Nal
R). We were surprised at the large number of prior false
calls with dHPLC, which was thought to be highly reliable until
now. Possibly, these false dHPLC calls reﬂect the fact that
dHPLC was performed with multiplexed DNA templates of 5 or
10 isolates in order to increase throughput and it was not sufﬁ-
ciently sensitive to signals from mixtures of alleles.
5
Mutation proﬁles for GyrA, GyrB and ParE of Salmonella
Typhi and Salmonella Paratyphi A
We also tested additional isolates of serovars Typhi (87 isolates)
and Paratyphi A (106 isolates) for which levels of susceptibility to
nalidixic acid were known (Table 3), but which had not been pre-
viously evaluated in regard to their DNA gyrase and topoisome-
rase SNP proﬁles. All Nal
S isolates of serovars Typhi (7 isolates)
and Paratyphi A (82 isolates) were wild-type for all alleles that
were tested. In contrast, mutations in GyrA or GyrA +ParE
were found in all Nal
R isolates of serovars Typhi (80 isolates)
and Paratyphi A (24 isolates). One of the Typhi isolates even con-
tained two mutations in GyrA (Table 3).
Overall, we have tested a total of 292 isolates of Salmonella
Typhi (Nal
R¼223 and Nal
S¼69) and 106 isolates of Salmonella
Paratyphi A (Nal
R¼24 and Nal
S¼82) with the Luminex assay.
All 247 Nal
R Salmonella Typhi and Salmonella Paratyphi A isolates
were found to harbour at least one of the target mutations,
which demonstrated 100% sensitivity for identifying Nal
R
mutations in this strain collection. The most common mutation
in the Nal
R Salmonella Typhi isolates was GyrA Phe-83 (143/
223¼64.1%). Three other less common mutation proﬁles were
GyrA Phe-83+ParE Asn-420 (33/223¼14.8%), GyrA Tyr-83 (27/
223¼12.1%) and GyrA Gly-87 (10/223¼4.5%). These four
mutation proﬁles account for 95.5% (213/223) of all Nal
R Salmo-
nella Typhi isolates that were tested. The predominating
mutation proﬁle of Salmonella Paratyphi A Nal
R isolates was
also GyrA Phe-83 (18/24¼75.0%).
GyrB mutations
The Luminex assay also recognized mutations in GyrB within
eight Nal
S Salmonella Typhi isolates (Table 4). Six of these iso-
lates are mutated at GyrB Phe-464, and one each at GyrB
Leu-465 and GyrB Asp-466. These isolates were designated
Nal
S, because their MICs of nalidixic acid are below the break-
point of 32 mg/L associated with resistance to nalidixic acid.
17
However, as shown in Table 4, all of them, except isolate
E98-4364, showed decreased susceptibility to ciproﬂoxacin,
which is of clear signiﬁcance in clinical practice. Different
groups have already reported such decreased ciproﬂoxacin
Table 2. Raw data of background-corrected MFI values for the 12 Salmonella Typhi isolates used for setting up the assay
a
Allele Amino acid
Salmonella Typhi isolates
CT18
b MP0150 150(98)S
b MP0247 MP0248 MP0327 8(04)N
b E02-2759
b MP0068 ct 42 MP0562 AG3
b H2O
gyrA247_C GyrA Pro-83 27.5 2331.5 17.0 26.0 22.0 0.5 16.0 19.0 22.0 25.5 17.0 11.0 15.0
gyrA247_T(+) GyrA Ser-83 2321.0 28.0 1639.0 1594.0 1497.0 1244.0 1850.0 1373.0 2349.0 2055.0 1864.5 1942.0 16.0
gyrA248_T GyrA Phe-83 25.0 10.0 2302.0 24.0 13.0 0.5 5.0 16.5 15.5 13.0 2784.0 2823.0 12.0
gyrA248_A GyrA Tyr-83 12.0 0.5 12.0 1610.0 12.5 0.5 0.5 1.0 13.5 22.5 17.0 19.0 15.0
gyrA248_C(+) GyrA Ser-83 1453.5 1129.5 7.5 5.0 1252.0 1100.5 1675.0 1972.0 1547.0 1845.0 31.5 27.0 16.5
gyrA259_A GyrA Asn-87 11.0 13.0 19.0 18.0 1969.0 1.0 12.0 13.0 19.0 18.5 14.0 15.0 18.0
gyrA259_T GyrA Tyr-87 16.0 25.0 23.0 22.5 17.0 1251.5 21.5 21.5 13.5 12.0 18.0 17.0 29.0
gyrA259_G(+) GyrA Asp-87 1621.5 1225.5 1226.5 1250.5 21.5 0.5 1657.5 1060.0 1673.5 2024.5 1554.5 1618.5 23.0
gyrA260_G GyrA Gly-87 25.0 24.0 19.0 22.0 19.0 9.0 3812.0 22.5 22.5 28.5 25.0 28.0 15.0
gyrA260_A(+) GyrA Asp-87 4591.5 3483.5 3562.5 3515.0 5238.0 1679.5 24.5 2769.5 4425.0 3078.5 4326.5 4733.5 14.5
gyrB1391_T GyrB Phe-464 15.0 18.0 19.0 26.0 26.0 9.0 12.0 1140.0 27.0 19.0 15.0 18.0 20.0
gyrB1391_C(+) GyrB Ser-464 1971.0 1718.0 1374.5 1478.0 1522.0 1592.0 1338.5 16.0 1974.0 1755.0 1427.0 1750.0 23.0
gyrB1394_T GyrB Leu-465 17.0 21.5 14.5 21.5 10.0 11.5 18.5 17.5 3005.5 24.5 18.5 11.5 16.0
gyrB1394_A(+) GyrB Gln-465 5961.0 5578.0 4700.0 5516.5 5372.0 2709.0 5198.0 1721.0 14.5 4967.0 5478.0 5935.0 15.0
gyrB1398_C GyrB Asp-466 27.5 18.5 22.0 2.5 21.5 10.0 10.5 0.5 16.5 3984.5 21.0 22.5 15.0
gyrB1398_A(+) GyrB Glu-466 4463.0 4221.0 3633.0 3550.0 3923.0 1634.0 3694.5 1486.5 1140.0 18.5 4045.0 4349.0 20.0
parE1246_T ParE Phe-416 20.0 22.5 16.0 20.0 22.0 14.5 17.0 16.0 20.0 21.0 2722.0 16.0 17.0
parE1246_C(+) ParE Leu-416 4119.5 3655.0 3842.0 3692.0 3833.0 2455.0 3866.0 3801.5 5039.0 4362.0 23.0 2382.0 25.0
parE1258_A ParE Asn-420 22.5 11.5 2.0 21.0 18.0 6.5 8.5 8.0 11.5 17.5 21.0 1918.5 24.0
parE1258_G(+) ParE Asp-420 1498.5 1388.0 1189.0 1178.5 1462.5 1762.0 1417.5 1158.0 1760.0 1636.5 1532.0 15.0 29.0
aThe MFI values were corrected by subtracting the value of the bead control; values of ,0 were arbitrarily set to 0.5. For easier visualization, the values
of called SNPs are shown in bold. The isolates MP0562 and AG3 contain dual mutations in gyrA and parE.
bIsolates from which whole genome sequences are available.
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Figure 3. Reproducibility of the Luminex assay in ﬁve independent tests with Salmonella Typhi CT18. (a) Raw data of average corrected MFI values (MFI
minus the MFI of bead control). Error bars indicate the standard deviation. (b) Ratios of MFIcalled allele/(MFIwild allele+MFImutant allele). The average ratio
for the called allele is shown, with error bars indicating the standard deviation.
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JACsusceptibility (DCS) isolates in Salmonella Typhi, for which the
ciproﬂoxacin MIC is 0.12–1 mg/L.
18–20 Patients infected with
DCS Salmonella Typhi isolates normally experience longer
times to fever clearance and more frequent treatment failure
than those without DCS.
18 According to Table 4,m u t a t i o n s
GyrB Phe-464 and GyrB Asp-466 seem to be responsible for
the DCS phenotype in some isolates, but this needs to be
further conﬁrmed by functional assays. It had already been
reported that isolates of Salmonella Typhimurium with GyrB
Phe-464+GyrA Phe-83+GyrA Asn-87 mutations were fully
resistant to ciproﬂoxacin (MIC 16–32 mg/L).
21 We therefore
considered it worthwhile to include these SNPs in the
Luminex assay. Thus, this assay recognizes two major
sources of decreased susceptibility to ﬂuoroquinolones,
only one of which is recognized by tests for resistance to
nalidixic acid.
Discussion
Luminex bead-based technology is a recently developed plat-
form for the detection of multiplexed signals. This system incor-
porates 5.6 mm polystyrene microspheres that are internally
labelled with two spectrally distinct ﬂuorochromes. Mixing
these two ﬂuorochromes in various proportions yields 100
types of distinguishable, commercially available beads, on the
basis of characteristic ﬂuorescence signals. In the past,
Luminex assays, also known as bead-based suspension arrays,
have been used predominantly for quantitative measurements
of multiplexed protein–ligand interactions or high-throughput
nucleic acid detection through DNA hybridization.
22,23 For
example, a Luminex hybridization assay has been introduced
to detect the six most common serogroups of S. enterica in the
USA.
24 Luminex assays are now being increasingly used for multi-
plexed genotyping on the basis of individual SNPs.
25 For example,
Ducey et al.
26 and Ward et al.
27 have presented Luminex-based
assays for genotyping Listeria monocytogenes,w h i c hc a ns i m u l -
taneously detect 51 or 64 SNPs on the basis of calibrated MFI
values.
We have developed a somewhat different strategy for the SNP
typing of bacterial DNA in this assay. Instead of attempting to
calibrate a range of acceptable MFI values that indicate a posi-
tive reaction, we designed ASPE primers that are speciﬁc for
both the mutated and the wild-type alleles at each targeted
polymorphic position. For Bips this involves one mutant-speciﬁc
and one wild-type-speciﬁc ASPE primer, while for Trips, such as
in gyrA, it involves two mutant-speciﬁc and one wild-type-
speciﬁc ASPE primer. The assay described here uses 20 ASPE
primers and 20 types of beads to screen three gene fragments
for 11 mutations, seven Bips and two Trips, and results in calls
for nine alternative alleles in each assay (Figure 3). This approach
has the disadvantage that two or three ASPE primers are needed
for each polymorphic site, but this disadvantage is accompanied
by very high reliability when measured as MFI ratios (Figure 3).
Table 3. Overview of mutation proﬁles for gyrA, gyrB and parE of all isolates included in this study
Mutation proﬁle Amino acid(s)
Validation panel
a Salmonella Typhi Salmonella Paratyphi A
Nal
R (n¼143) Nal
S (n¼62) Nal
R (n¼80) Nal
S (n¼7) Nal
R (n¼24) Nal
S (n¼82)
Wild-type wild-type 54 7 82
gyrA247_C GyrA Pro-83 1
gyrA248_T GyrA Phe-83 77 66 18
gyrA248_A GyrA Tyr-83 18 9 3
gyrA259_A GyrA Asn-87 4 2 2
gyrA259_T GyrA Tyr-87 1 1
gyrA260_G GyrA Gly-87 10
gyrB1391_T GyrB Phe-464 6
gyrB1394_T GyrB Leu-465 1
gyrB1398_C GyrB Asp-466 1
gyrA248_T, parE1246_T GyrA Phe-83, ParE Phe-416 1
gyrA248_T, parE1258_A GyrA Phe-83, ParE Asn-420 31 2
gyrA248_T, gyrA259_A GyrA Phe-83, GyrA Asn-87 1
aThe validation panel consists of Salmonella Typhi isolates for which dHPLC results on gyrA, gyrB and parE are available, including the 12 isolates in
Table 2 used for setting up the assay.
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Table 4. Characteristics of Salmonella Typhi isolates with GyrB
mutations
Isolate Year Country
NAL MIC
(mg/L)
a
CIP MIC
(mg/L)
b
GyrB
mutation
AG-22 2004 Vietnam 6.0 0.250 Phe-464
AS-22541 2003 Bangladesh 8.0 0.125 Phe-464
DT-33 2002 Vietnam 8.0 0.500 Phe-464
DT-94 2002 Vietnam 16.0 0.125 Phe-464
dty1-121 1997 Vietnam 8.0 0.190 Phe-464
E02-2759 2002 India 4.0 0.125 Phe-464
ct 42 1994 Vietnam 16.0 0.160 Asp-466
E98-4364 1998 Mexico 2.0 0.030 Leu-465
aMIC of nalidixic acid (NAL), which ranges from 0.75 to 4.0 mg/L for 25
isolates without mutations.
bMIC of ciproﬂoxacin (CIP), which ranges from 0.012 to 0.032 mg/L for 25
isolates without mutations.
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controls for analysing real samples, which improves the overall
throughput. In other assays that have been described, such as
dHPLC
8,28 and high-resolution melting curve assays,
13 SNPs are
called by examining the curves (including shape and melt temp-
erature/retention time), which can be subject to human errors.
Positive controls for every genotype should also be included in
every assay batch when using these two technologies, to
ensure reliable comparisons and SNP callings.
Another underlying advantage of using ASPE speciﬁc for both
the mutation and wild-type alleles is that this approach provides
a limited ability for mutation discovery. Failure to call any SNP for
all ASPE primers within one of the three multiplexed gene frag-
ments implies polymorphisms within the PCR primer-binding
region, which we have not yet observed. On the other hand, if
only certain mutations are not called in one fragment, this indi-
cates the existence of novel sequence diversity within the ASPE
primer binding sites. In its original form, when the assay had
been developed only for Salmonella Typhi, it failed to call SNPs
in codons 465 and 466 in gyrB for Salmonella Paratyphi A iso-
lates. This proved to reﬂect two silent mutations in the gyrB of
Salmonella Paratyphi A isolates (Figure 1b), which signiﬁcantly
reduced the ASPE efﬁciency for neighbouring target mutations.
After introducing appropriate degenerate nucleotides into the
ASPE primers, the assay now also works well for Salmonella Para-
typhi A. Similarly, the Luminex assay failed to call SNPs in codon
464 of gyrB in two Salmonella Typhi isolates, which subsequently
turned out to harbour a novel mutation in this codon (F.-X. Weill,
unpublished data).
Glass slide-based microarray technology can potentially offer
similar or even much higher multiplexing capacity in terms of
numbers of targeted mutations. For instance, a microarray has
been described that simultaneously scans all potential
mutations in codons 83 and 87 of gyrA in extraintestinal patho-
genic Escherichia coli, as well as mutations inside the virulence-
related gene ﬁmH.
29 However, the glass slide-based microarray
can only test one sample per slide, with a maximum throughput
of dozens of samples per day. The Luminex assay presented here
offers higher throughput (11 SNPs for 188 isolates per day).
Although the current Luminex protocol is not simple enough
yet for routine use in hospitals with limited numbers of
samples, it will be ideal for reference laboratories and central
clinical laboratories with large sample collections. The total
cost of this assay per sample (including oligos, reagents and
xTAG beads) was  E2.40 (US$ 3.50), which means  E0.20 per
SNP. For testing large numbers of samples, it might be possible
to reduce costs dramatically by using an oligonucleotide ligation
assay with very low numbers of beads.
30
The Luminex assay identiﬁed one or two mutations in each
Nal
R isolate that was tested (100% sensitivity), resulting in
nine distinct mutation proﬁles (genotypes) of Nal
R Salmonella
Typhi and four proﬁles of Nal
R Salmonella Paratyphi A (Table 3).
All the single mutations of gyrA were located in codons 83 and
87, which are known to represent ‘hotspots’ of Nal
R mutations
in Salmonella.
4,6 The three dual-mutation proﬁles of Salmonella
Typhi might reﬂect the accumulation of point mutations in
GyrA and ParE under the selection of ﬂuoroquinolone usage for
therapy.
31
Several papers reported mutations of ParC in ciproﬂoxacin-
resistant Salmonella Typhi and Salmonella Paratyphi A
isolates.
32–34 We failed to identify any resistant strain with a
ParC mutation in our current Salmonella Typhi and Salmonella
Paratyphi A collections; therefore, we excluded ParC from the
assay due to the lack of control isolates for assay validation.
We also did not include probes for plasmid-mediated quinolone
resistance [qnrA, qnrB, qnrC, qnrS, qepA and aac(6′)-Ib-cr]
35,36 or
quinolone resistance related to decreased antibiotic uptake
(mar and acr genes),
6 which were only reported in some sero-
vars of S. enterica other than Typhi and Paratyphi A. However,
the assay presented in this paper can potentially be extended
to detect additional quinolone-resistance-related mutations in
Salmonella. Luminex is currently bringing a hardware upgrade
to market that can distinguish 500 analytes (capable of
testing 250 Bips) and it would also be possible to combine
multiple SNP typing with direct-hybridization tests in the
same assays. Probably, the most limiting feature of the
Luminex assay is the number of multiplexed PCR products
that can simultaneously be ampliﬁed. One human genetic
study reported successful 15-plex and 40-plex SNP genotyp-
ing,
30 and we have succeeded in developing an 18-plex assay
for genotyping Salmonella Typhi (Y. Song and M. Achtman,
unpublished data). For extending this assay to detect SNPs in
QRDRs of some other common serovars of Salmonella (Typhi-
murium, Enteritidis, Dublin etc.), multiplex PCR is not likely to
be a problem, as it will only need to amplify four genes
(gyrA, gyrB, parC and parE). Since there are more mutations
in QRDRs of other Salmonella serovars than what we have
tested here,
6 careful alignments of the targeted regions must
be performed before designing ASPE primers (Figure 1). Degen-
erate nucleotides will be necessary to cover the variations
inside the upstream regions ( 8 bp) of certain targeted
mutations; this has been proven as an effective strategy for
gyrA and gyrB in this study (Table 1).
In summary, we describe a ﬂexible, rapid, medium through-
put and cost-effective multiplexed Luminex xTAG assay, which
can simultaneously detect 11 mutations in gyrA, gyrB and
parE of Salmonella Typhi and Salmonella Paratyphi A. This
assay yields unambiguous SNP calls and possesses a limited
mutation discovery potential. It can be used on extracted
DNA or on single colonies of Salmonella Typhi and Salmonella
Paratyphi A, which makes it an ideal platform for clinical and
reference laboratories to rapidly screen quinolone-resistant Sal-
monella Typhi and Salmonella Paratyphi A isolates for guiding
therapy, and detect the underlying genetic changes for molecu-
lar epidemiological analysis. The genotyping assay presented
here can also be readily adapted to decipher evolutionary
events and detailed population genetics in a variety of other
genetically monomorphic bacterial pathogens, such as Salmo-
nella Typhi, Yersinia pestis, Bacillus anthracis and Mycobacterium
tuberculosis, in which SNPs can serve as reliable genetic
markers.
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